SciLifeLab (Science for Life Laboratory) is Sweden’s national center for molecular biosciences, with the mission to provide a unique and enabling infrastructure to the life science community, facilitate internationally leading collaborative science, and promote the translation of biomolecular research findings into lasting societal benefits.
As part of the Nordic Life Science Days 2018, we invite you to attend a one-day satellite symposium to learn more about SciLifeLab, meet our facilities, investigate our capabilities and technologies, and further develop how your organization can leverage this unique asset in Sweden’s life science sector.
The symposium is free of charge and exclusive for registered participants of NLSDays. If you have not yet registered for NLSDays, please visit www.nlsdays.com. The event is held in Aula Medica at Karolinska Institutet on Monday 10 September 2018, between 10:00–15:00. Bus service round trip from Stockholm Waterfront will be provided.
Welcome to sign up now at:
Get ready to pitch!
Now is your chance to make a lasting first impression and establish yourself and your company with the Nordic region’s foremost investors. Prepare your 1-minute video pitch and fill in your Startup Challenge application today!
Startup Challenge at Nordic Life Science Days, NLSDays, at Waterfront in Stockholm, evening of the 10th of September. This year Umeå Biotech Incubator will be hosting the event with Pfizer as sponsor.
Startup Challenge is an enjoyable pitching event showcasing the best and brightest startups currently emerging from the nordic life science ecosystem. Based on your video contributions, the best 12 will be selected to pitch live in front of hundreds of life science industry investors. It means that you will be pitching in front of a qualified audience. The winner receives a free admission with company presentation to the Nordic Life Science Days 2019.
Benefit from the ideal environment for your company to engage with the leaders in life science, NLSDays being an excellent opportunity to interact with people who have a successful track record and a great place to meet potential investors and partners. On the top of that, it will be fun! You will also get exposure through the website and the program for the conference.
What to do?
Checkpoints before you fill in your application
…If everything is in order, good! Now, follow these instructions:
Great! Now you’re in the running towards becoming the next winner of the Startup Challenge 2018. Good luck!
Competition criteria and setup
The jury who consist of selected and experienced investors will give every video pitch score on a scale 1-7 based on these following judgement criteria:
The 12 cases with the highest points will go to the finals and get to live pitch in front on hundreds important investors at NLSDays Startup Challenge 10th of September.
The live pitch must be 2 minutes long and the audience at the Startup Challenge at NLSDays will decide on site through live digital voting who the winner is, so it’s important to capture the audience! The winner will be announced on stage by a representative from Pfizer.
The lucky winner of the Startup Challenge 2018 will receive a free entrance to NLSdays 2019 + a free company presentation. That’s huge!
Everyone is a winner!
All Startup Challenge applicants will get registration discounts for the entrance to NLSdays 2018.
For all Startup Challenge applicants (not selected for the finals but has fulfil the application criteria):
For selected finalists:
If you are interested in benefiting from the different registration discounts, please contact Jennie Ekbeck at Umeå Biotech Incubator to receive your discount code.
Hope to see you at the Startup Challenge @NLSDays 2018!
Best wishes from Umeå Biotech Incubator – growing ideas that can change the world
Starting and evolving a company requires funds. This session is aimed at helping you better navigate the jungle of financing. We will take you through inspiring journeys that will be discussed by an experienced panel of investors, from Business Angels to Venture Capital firms.
Patient engagement in very much in vogue, but does it really make a difference and how can we measure this? This session will look at what patient engagement actually means in practical terms, and its impact as a business development tool, drawing on concrete good practice examples from the rare diseases community and personalised medicines.
We will also explore
Visionary companies exploit nano-features to boost pharma- and medical device products. Scientific, financial and commercial perspectives of nanomedicine will be covered.
Moderator: Mr. Patrick Boisseau - Programme Manager on Nanomedicine, CEA-Leti
Technology gives access to a wealth of data and enables personalized care in an increasingly connected world. Future innovation in life science is about integrating medtech, pharmaceuticals and digital solutions. It requires innovative thinking in many dimensions.
How can we increase cooperation to integrate these areas more?
The regulatory requirements within pharma are challenging. The crusial question is how to handle the rapid development and take advantage of digital health solutions.
Many SME companies focused on drug development choose to work according a virtual business model where key expertise is contracted ad hoc for specific tasks. Often also more general tasks such as project management may be covered by contracted staff. The virtual model is attractive because it adds flexibility and supports the agile organization. On the other hand, working virtually requires additional care when considering what tasks to outsource and criteria for selection of vendors.
The session “The Virtual Business Model” will focus on “WHY”, “WHEN” and “HOW” from a company management perspective. When will virtual competence add the extra edge are there situation when the virtual model is not advantageous?
The speaker list includes speakers experienced in working in a virtual business model as well as companies supplying virtual services.
Opportunities within precision and personalized medicine attracts much interest, not only from scientists, drug markers and patients but also from funders and decision makers.
Alongside opportunities, however, there are also several challenges to overcome to ensure successful launch and implementation of truly personalized therapies.
The changes required for drug manufacturers, healthcare providers and payers are radical and transformative, and involves the full value chain with all its stakeholders.
With its recent first-to-launch CAR-T therapy introduction in the US, Novartis is now preparing for launch of the therapy also in Europe.
This session will talk about what it will really take from the healthcare ecosystem players when preparing for taking full advantage of the promising new precision treatments currently being developed in many important disease areas.
Drug delivery is the science of getting the right amount of active drug to the right place in the body at the right time. The area of drug delivery has increased in importance as the medical needs continuously present new challenges to us and new and more complex treatment modalities are developed. In some of these modalities the drug delivery system and the active pharmaceutical ingredient (API) will be integrated to form the therapy and need to be fully aligned. Furthermore, challenges such as patient adherence, paediatrics/geriatrics and personalized medicine present challenges where innovative drug delivery solutions can add huge value to patients and society.
In this session, we will have presentations from three ongoing research initiatives related to advanced drug delivery: Sweden Drug Delivery Forum, NextBioForm and FoRmulaEx. We will also get a brief introduction to the industry network Sweden Drug Delivery Industry Group and get some messages from the sponsors of this session. Finally, a short panel discussion with the presenters discussing the future challenges and new opportunities will finish off the session.
Given you sometimes only get one chance to tell your story right, its essential that pitch it appropriately to investors. This session will provide an opportunity to hear from leading life science investors to better understand their areas of interest and investment criteria and what they would like to hear from you.
The pitching session will be followed by an interactive QA session to provide the audience with an opportunity to ask questions.
This Super Session gathers top experts from the pharmaceutical and private fertility industry who will discuss the business and the industries perspective on reproductive medicine.
Every 12th child is conceived in a fertility clinic. 16-25 % of couples that try to get pregnant have fertility problems. The birth rate has fallen drastically over the past 50 years and most countries have fertility rate of less than 1,5 children per woman. The combination of demographic development and the low fertility rates demands new solutions and services. This development creates new business opportunities for the private fertility sector.
This session is hosted by ReproUnion – _a cross border collaboration between Sweden and Denmark within the area of reproductive medicine. The collaborative network consists of 14 clinical and research units within the Capital Region of Denmark, Region Zealand of Denmark and Region Skåne in Southern Sweden.
Dr. Stig Jørgensen - Program Director ReproUnion Dr. Rita Vassena - Scientific Director, Eugin, Executive Member of ESHRE Dr. Henk Jan Out - VP Reproductive Medicine & Women’s Health, Ferring Pharmaceuticals
At this session, international experts from pharma, biotech, academia and the investment community will discuss how big data, personalized medicine, beyond the pill approaches, new targets, an increased understanding of the microbiome and insights from neuroscience could address these challenges and shape the next wave of innovation in Immuno-Oncology (I-O).
Over the past few years, the rapid development of novel cancer immunotherapy approaches has fundamentally disrupted the oncology space. I-O has not only become a key component of cancer therapy, but it has also reshaped priorities in oncology R&D across the industry, with unprecedented clinical success in certain cancer types continuing to fuel record investment and partnering activity. As of today, more than 2.000 I-O agents, including checkpoint-inhibitors, vaccines, oncolytic viruses and cellular therapies, are in preclinical or clinical development
Yet, still only a minority of patients benefits from effective and durable I-O treatments. Beyond resistance or unexplained lack of response, which could be addressed through a better understanding of optimal timing of therapy, better combination therapy design, or improved patient selection, a lack of novel targets and of an overall better understanding of specific immune mechanisms is becoming a roadblock to further advance in the space.
Moderator: Dr. Gaspar Taroncher-Oldenburg - Editor-at-Large, Nature Publishing Group
Dr. Richa Wilson - Associate Director, Digital and Personalized Healthcare, Roche Partnering Dr. Emilio Erazo-Fischer - Associate Director of Global Oncology BD, Boehringer Ingelheim Dr. Erica Sloan - Group Leader, Cancer & Neural-Immune Research Lab, Monash University Mr. Peter Benson - Co-founder and Managing Partner, Sunstone Life Science Ventures Dr. Simon Skjøde Jensen - CEO and Co-Founder, MonTa Biosciences
The fast growing amount of biobank and health data presents an unparalled opportunity for drug target and biomarker discovery, Real Worl Evidence-based research (RWE) and personalized healthcare.
However, this opportunity presents also a challenge on how to make sense of this data and find medically meaningful discoveries.
The application of artificial intelligence (AI) solutions may provide one answer to this medical needle in a hay stack problem and help us conquer the burder of common diseases such as diabetes, cancer and neurological diseases.